Sanofi : Dupixent Shows Superior Results To Xolair In Phase 4 Study For Sinus And Asthma Treatment

Sanofi and Regeneron reported positive Phase 4 EVEREST study results, demonstrating Dupixent's superiority over Xolair in treating severe chronic rhinosinusitis with nasal polyps (CRSwNP) in adults with coexisting asthma. Dupixent outperformed Xolair across all primary and secondary endpoints related to CRSwNP and asthma, reinforcing its efficacy in treating both upper and lower respiratory diseases by targeting IL-4 and IL-13. The safety profiles of both drugs were consistent with previous findings, with similar overall rates of adverse events.

Analysis

Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) announced positive results from the EVEREST Phase 4 study, where Dupixent (dupilumab) demonstrated superiority over Xolair (omalizumab) in treating adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma. Dupixent outperformed Xolair across all primary and secondary efficacy endpoints for CRSwNP, as well as all asthma-related endpoints, reinforcing its efficacy in treating both upper and lower respiratory diseases by targeting IL-4 and IL-13—key drivers of type 2 inflammation. The safety profile of Dupixent was generally consistent with its known profile; overall adverse event (AE) rates were similar for Dupixent (64%) versus omalizumab (67%), while serious AEs were notably lower for Dupixent at 2% compared to 4% for omalizumab. Adverse events leading to study discontinuation were 3% for Dupixent and 1% for omalizumab. These findings significantly strengthen Dupixent's clinical differentiation and competitive standing against Xolair, supporting its continued growth trajectory in the substantial market for type 2 inflammatory conditions.

Key Decisions for Investors

• Investors should assess the potential for accelerated market share gains for Dupixent against Xolair in the CRSwNP with asthma segment, positively impacting revenue forecasts for Sanofi (SNY) and Regeneron (REGN).
• The superior efficacy and favorable serious adverse event profile (2% for Dupixent vs. 4% for Xolair) strengthen Dupixent's competitive positioning, warranting a review of valuation multiples for both SNY and REGN.
• Monitor physician adoption patterns and potential updates to treatment guidelines, as these results could solidify Dupixent as a preferred treatment option, while noting the slightly higher discontinuation rate due to AEs (3% vs 1%) as a minor factor in the overall positive profile.